Rapamycin for longevity: the pros, the cons, and future perspectives.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or new human data
PubMed 40620657 · doi:10.3389/fragi.2025.1628187
What was done
This narrative review synthesizes literature on the mTOR pathway, the pharmacological actions of rapamycin and its analogs, and their potential application for longevity and age-related disease prevention. The authors analyze mechanistic rationale, existing off-label use, knowledge gaps, and regulatory precedents from the approval of everolimus for tuberous sclerosis complex-related seizures.
What was found
The abstract reports no numerical findings or primary trial results. It notes that mTOR signaling accelerates aging and contributes to cancer, atherosclerosis, diabetes, and immune decline. While rapamycin and rapalogs are FDA-approved for organ transplant rejection and tuberous sclerosis complex, their use for human longevity remains off-label without broad clinical endorsement.
Why it matters
The paper contextualizes the growing off-label interest in mTOR inhibitors among clinicians and individuals against the lack of formal clinical validation and regulatory approval for longevity.
Limits
As a narrative review, the paper presents no new human data, randomized trials, or systematic search methodology. It reports no quantitative effect sizes, optimal dosing strategies, or safety outcomes for healthy populations.
Cited by
- supports Sirolimus (rapamycin) is FDA-approved for the prevention of organ transplant rejection.
- supports Rapamycin (sirolimus) was approved by the FDA for the prevention of organ transplant rejection.